ERS Genomics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

ERS Genomics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH2298732D
  • |
  • Pages: 23
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

ERS Genomics Ltd (ERS Genomics) is a provider of genomic editing technologies. The company offers clustered regularly interspaced short palindromic repeats (CRISPR), a proprietary technology which uses a complex molecule that contains protein cas9 with one or more guide ribonucleic acids that binds to the genome in living cells at any preferred locations. Its CRISPR technology can be used to change the deoxyribonucleic acid sequence at the targeted locations. It has intellectual property license for CRISPR-cas9 that can be used for genome editing in all the living organisms. The company offers non-exclusive licenses to other companies for internal research and sale of products and services in the areas of research tools, kits, reagents; molecular diagnostics, synthetic biology, and others. ERS Genomics is headquartered in Dublin, Ireland.

ERS Genomics Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ERS Genomics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ERS Genomics Ltd, Medical Devices Deals, 2012 to YTD 2018 8

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Licensing Agreements 10

University of Tubingen and NMI TT Pharmaservices Enters into Licensing Agreement with ERS Genomics 10

Evotec Enters into Licensing Agreement with ERS Genomics 11

Oxford Genetics Enters into Licensing Agreement with ERS Genomics 12

CRISPR Therapeutics Enters into Licensing Agreement with Intellia Therapeutics, Caribou Biosciences, ERS Genomics, University of California and University of Vienna 13

Knudra Transgenics Enters into Licensing Agreement with ERS Genomics 15

Horizon Discovery Extends Licensing Agreement with ERS Genomics 16

Bayer Enters into Licensing Agreement with ERS Genomics 17

Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 18

ERS Genomics Ltd-Key Competitors 19

ERS Genomics Ltd-Key Employees 20

ERS Genomics Ltd-Locations And Subsidiaries 21

Head Office 21

Recent Developments 22

Legal and Regulatory 22

Apr 13, 2017: CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision 22

Appendix 23

Methodology 23

About GlobalData 23

Contact Us 23

Disclaimer 23

List of Figures

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ERS Genomics Ltd, Medical Devices Deals, 2012 to YTD 2018 8

List of Tables

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Key Facts 2

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ERS Genomics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ERS Genomics Ltd, Medical Devices Deals, 2012 to YTD 2018 8

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

University of Tubingen and NMI TT Pharmaservices Enters into Licensing Agreement with ERS Genomics 10

Evotec Enters into Licensing Agreement with ERS Genomics 11

Oxford Genetics Enters into Licensing Agreement with ERS Genomics 12

CRISPR Therapeutics Enters into Licensing Agreement with Intellia Therapeutics, Caribou Biosciences, ERS Genomics, University of California and University of Vienna 13

Knudra Transgenics Enters into Licensing Agreement with ERS Genomics 15

Horizon Discovery Extends Licensing Agreement with ERS Genomics 16

Bayer Enters into Licensing Agreement with ERS Genomics 17

Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 18

ERS Genomics Ltd, Key Competitors 19

ERS Genomics Ltd, Key Employees 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

ERS Genomics Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17975
Site License
USD 500 INR 35950
Corporate User License
USD 750 INR 53925

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com